400 R&D jobs cut as Novo Nordisk says goodbye to inflammatory work

By Fiona BARRY

- Last updated on GMT

Novo Nordisk HQ
Novo Nordisk HQ

Related tags Novo nordisk Inflammation

Novo Nordisk has scrapped all its inflammatory disease therapy development programmes, cutting 400 jobs. 

The company announced it will stop R&D for inflammatory disorders within six months to concentrate on its diabetes and obesity pipelines.

A spokesman for Novo Nordisk told in-Pharmatechnologist.com the company expects to be able to offer other jobs to around half of the 400 employees affected.

The people who will be most difficult to redeploy are those who are very specialized within inflammatory disorders,​” said Mike Rulis.

There are no plans to outsource some of our R&D work and no plans to sell assets in the form of API or manufacturing equipment, but we are evaluating options for out-licensing some of the projects we have discontinued.​” 

Closing down its anti-inflammatory activities will cost Novo Nordisk around 700m Danish kroner (€93m), of which 400m kroner relates to impairment of intangible assets, and 300m kroner comes from other exit costs such as project closures and severance payments.

The news follows an announcement by the Danish pharma giant earlier this year of plans to discontinue its most advanced anti-inflammatory candidate, for the treatment of rheumatoid arthritis.

The discontinuation of anti-IL-20 delays our earliest possible entrance into the market for anti-inflammatory therapeutics to the late 2020s,​” said Mads Krogsgaard Thomsen, executive VP and Chief Science Officer.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more